• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-A12G filed by Statera Biopharma Inc.

    2/1/23 4:08:16 PM ET
    $STAB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $STAB alert in real time by email
    8-A12G 1 cbli20230130_8a12g.htm FORM 8-A12G cbli20230130_8a12g.htm

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     


     

    FORM 8-A

     


     

    FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES

    PURSUANT TO SECTION 12(b) OR 12(g) OF THE

    SECURITIES EXCHANGE ACT OF 1934

     


     

    Statera Biopharma, Inc.

    (Exact name of registrant as specified in its charter)

     


     

    Delaware

     

    20-0077155

    (State or other jurisdiction of

    incorporation or organization)

     

    (IRS Employer

    Identification No.)

       

    2580 East Harmony Road, Suite 316

    Fort Collins, CO 80528

     

    80528

    (Address of principal executive offices)

     

    (Zip Code)

     

    Securities to be registered pursuant to Section 12(b) of the Act:

     

    Title of each class

    to be so registered

     

    Name of each exchange on which

    each class is to be registered

    Not Applicable

     

    Not Applicable

     

    If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c) or (e), check the following box. ☐

     

    If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d) or (e), check the following box. ☒

     

    If this form relates to the registration of a class of securities concurrently with a Regulation A offering, check the following box. ☐

     

    Securities Act registration statement or Regulation A offering statement file number to which this form relates: N/A (if applicable)

     

    Securities to be registered pursuant to Section 12(g) of the Act:

     

    Series B Preferred Stock,

    par value $0.005 per share

    (Title of class)

     



     

     

     

     

    Item 1.

    Description of Registrant’s Securities To Be Registered.

     

    On January 26, 2023, the board of directors (the “Board”) of Statera Biopharma, Inc. (the “Company”) declared a dividend of one one-thousandth of a share of Series B Preferred Stock, par value $0.005 per share (“Series B Preferred Stock”), for each outstanding share of the Company’s common stock, par value $0.005 per share (“Common Stock”) to stockholders of record at 5:00 p.m. Eastern Time on February 1, 2023 (the “Record Date”).

     

    The preferences, rights, limitations and other matters relating to the Series B Preferred Stock are set forth in a Certificate of Designation of Preferences, Rights and Limitations of Series B Preferred Stock (the “Certificate of Designation”).

     

    General; Transferability. Shares of Series B Preferred Stock will be uncertificated and represented in book-entry form. No shares of Series B Preferred Stock may be transferred by the holder thereof except in connection with a transfer by such holder of any shares of Common Stock held by such holder, in which case a number of one one-thousandths (1/1,000ths) of a share of Series B Preferred Stock equal to the number of shares of Common Stock to be transferred by such holder will be automatically transferred to the transferee of such shares of Common Stock.

     

    Voting Rights. Each share of Series B Preferred Stock will entitle the holder thereof to 1,000,000 votes per share (and, for the avoidance of doubt, each fraction of a share of Series B Preferred Stock will have a ratable number of votes). Thus, each one-thousandth of a share of Series B Preferred Stock would entitle the holder thereof to 1,000 votes. The outstanding shares of Series B Preferred Stock will vote together with the outstanding shares of Common Stock of the Company as a single class exclusively with respect to (1) any proposal to adopt an amendment to the Company’s restated certificate of incorporation, as amended (the “Certificate of Incorporation”), to increase the number of authorized shares of Common Stock from 150,000,000 shares to 250,000,000 shares and to reflect a corresponding increase in the total number of shares the Corporation is authorized to issue from 151,000,000 shares to 251,000,000 shares (the “Authorized Share Increase”), (2) any proposal to adopt an amendment to the Certificate of Incorporation to effect a reverse stock split at a ratio of not less than 1-for-10 and not greater than 1-for-300, with the exact ratio, if approved and effected at all, to be set within that range at the discretion of the Board and publicly announced by the Company on or before March 11, 2024 without further approval or authorization of the stockholders (the “Reverse Stock Split”), and (3) any proposal to adjourn any meeting of stockholders called for the purpose of voting on the Authorized Share Increase and the Reverse Stock Split (the “Adjournment Proposal”). The Series B Preferred Stock will not be entitled to vote on any other matter, except to the extent required under the Delaware General Corporation Law. 

     

    Unless otherwise provided on any applicable proxy or ballot with respect to the voting on the Authorized Share Increase, the Reverse Stock Split or the Adjournment Proposal, the vote of each share of Series B Preferred Stock (or fraction thereof) entitled to vote on the Authorized Share Increase, the Reverse Stock Split and the Adjournment Proposal brought before any meeting of stockholders held to vote on such matters shall be cast in the same manner as the vote, if any, of the share of Common Stock (or fraction thereof) in respect of which such share of Series B Preferred Stock (or fraction thereof) was issued as a dividend is cast on the Authorized Share Increase, the Reverse Stock Split and the Adjournment Proposal, and the proxy or ballot with respect to shares of Common Stock held by any holder on whose behalf such proxy or ballot is submitted will be deemed to include all shares of Series B Preferred Stock (or fraction thereof) held by such holder. Holders of Series B Preferred Stock will not receive a separate ballot or proxy to cast votes with respect to the Series B Preferred Stock on the Authorized Share Increase, the Reverse Stock Split or the Adjournment Proposal brought before any meeting of stockholders held to vote on such matters.

     

    Dividend Rights. The holders of Series B Preferred Stock, as such, will not be entitled to receive dividends of any kind.

     

     

     

     

    Liquidation Preference. The Series B Preferred Stock will rank senior to the Common Stock as to any distribution of assets upon a liquidation, dissolution or winding up of the Company, whether voluntarily or involuntarily (a “Dissolution”). Upon any Dissolution, each holder of outstanding shares of Series B Preferred Stock will be entitled to be paid out of the assets of the Company available for distribution to stockholders, prior and in preference to any distribution to the holders of Common Stock, an amount in cash equal to $0.005 per outstanding share of Series B Preferred Stock.

     

    Redemption. All shares of Series B Preferred Stock that are not voted by duly returning a proxy card prior to the opening of any meeting of stockholders held to vote on the Authorized Share Increase, the Reverse Stock Split and the Adjournment Proposal will automatically be redeemed in whole, but not in part, by the Company as of immediately prior to the opening of such meeting (the “Initial Redemption Time”) without further action on the part of the Company or the holder of shares of Series B Preferred Stock (the “Initial Redemption”). Any outstanding shares of Series B Preferred Stock that have not been redeemed pursuant to an Initial Redemption will be redeemed in whole, but not in part, automatically upon the approval by the Corporation’s stockholders of the Authorized Share Increase and the Reverse Stock Split at any meeting of stockholders held for the purpose of voting on such proposals. Notwithstanding the foregoing, the Board may, in its sole discretion and at any time, order redemption of all, but not part, of the outstanding shares of Series B Preferred Stock by delivering written notice of redemption to each holder of record of outstanding shares of Series B Preferred Stock not less than two (2) days prior to the redemption date specified in such notice.

     

    Each share of Series B Preferred Stock redeemed in any redemption described above will be redeemed in consideration for the right to receive an amount equal to $0.005 in cash for each whole share of Series B Preferred Stock that are “beneficially owned” by the “beneficial owner” (as such terms are defined in the Certificate of Designation) thereof as of immediately prior to the applicable redemption time and redeemed pursuant to such redemption. However, the redemption consideration in respect of the shares of Series B Preferred Stock (or fractions thereof) redeemed in any redemption described above: (i) will entitle the former beneficial owners of less than two whole shares of Series B Preferred Stock redeemed in any redemption to no cash payment in respect thereof and (y) will, in the case of a former beneficial owner of a number of shares of Series B Preferred Stock (or fractions thereof) redeemed pursuant to any redemption that is not equal to a whole number that is a multiple of two, entitle such beneficial owner to the same cash payment, if any, in respect of such redemption as would have been payable in such redemption to such beneficial owner if the number of shares (or fractions thereof) beneficially owned by such beneficial owner and redeemed pursuant to such redemption were rounded down to the nearest whole number that is a multiple of two (such, that for example, the former beneficial owner of 21.5 shares of Series B Preferred Stock redeemed pursuant to any redemption will be entitled to receive the same cash payment in respect of such redemption as would have been payable to the former beneficial owner of 20 shares of Series B Preferred Stock redeemed pursuant to such redemption).

     

    Miscellaneous. The distribution of the Series B Preferred Stock is not expected to be taxable to stockholders or to the Company. However, stockholders may, depending upon the circumstances, recognize taxable income in the event of the redemption of the Series B Preferred Stock as described above. The Series B Preferred Stock is not convertible into, or exchangeable for, shares of any other class or series of stock or other securities of the Company. The Series B Preferred Stock has no stated maturity and is not subject to any sinking fund. The Series B Preferred Stock is not subject to any restriction on the redemption or repurchase of shares by the Company while there is any arrearage in the payment of dividends or sinking fund installments.

     

    * * * * *

     

    The foregoing description of the Series B Preferred Stock does not purport to be complete and is qualified in its entirety by reference to the Certificate of Designation, which is filed as Exhibit 3.1 hereto and is incorporated herein by reference.

     

     

     

     

     

    Item 2.

    Exhibits.

     

    Exhibit

    No.

     

    Description

       

    3.1

     

    Certificate of Designation of Preferences, Rights and Limitations of Series B Preferred Stock of the Company, dated January 31, 2023.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized.

     

     

    Statera Biopharma, Inc. 

     

     

     

     

     

     

     

     

     

    Date: February 1, 2023

    By:

    /s/ Michael K. Handley

     

     

    Name:

    Michael K. Handley

     

     

    Title:

    Chief Executive Officer

     

     

     
    Get the next $STAB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $STAB

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $STAB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Tivic Health Acquires Exclusive Worldwide Rights to Phase III TLR5 Agonist from Statera Biopharma

      Broad licensing agreement accelerates Tivic's transformation into a diversified therapeutics company, adds late-stage immunotherapeutic to clinical pipeline. Potential for FDA approval within 24 months. Tivic Health Systems, Inc., (NASDAQ:TIVC) today announced it has acquired worldwide exclusive license rights from Statera Biopharma (OTC:STAB) to the late-stage Toll-like Receptor 5 (TLR5) agonist Entolimod™ for the treatment of acute radiation syndrome (ARS). In addition, the company has acquired an exclusive option to license five additional indications and clinical use cases for Entolimod and its derivative, Entalasta™. This broad licensing agreement establishes Tivic as a diversified t

      2/12/25 8:30:00 AM ET
      $STAB
      $TIVC
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
    • CRAIG D. LINDER SELECTED TO 2024 TOP 50 LAWYERS IN AMERICA

      WEST PALM BEACH, Fla., April 11, 2024 /PRNewswire/ --   Anthony, Linder & Cacomanolis, PLLC is proud to announce that Partner Craig D. Linder has been selected to the 2024 Top 50 Lawyers in America list for securities law. This prestigious accolade is part of the 10th annual list honoring a select group of 50 lawyers who have demonstrated outstanding leadership and success within the securities law community in the Americas. America's Top 50 Lawyers identifies and highlights the accomplishments of the nation's most distinguished and skilled attorneys in all fields of practice of law. Only 50 lawyers in each state will receive this honor and be selected for this esteemed membership. This hon

      4/11/24 10:00:00 AM ET
      $FUBO
      $HOUR
      $HTCR
      $MOBQ
      Movies/Entertainment
      Consumer Discretionary
      Catalog/Specialty Distribution
      EDP Services
    • Statera Biopharma Signs Letter of Intent for Merger with Worksite Labs

      FORT COLLINS, Colo., March 15, 2023 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (OTCPK:STAB) (the "Company" or "Statera Biopharma"), a biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, is pleased to announce it has entered into a non-binding letter of intent (the "LOI") with Worksite Labs, Inc. ("WSL"), setting out the initial proposed terms and conditions pursuant to which the Company and Worksite Labs intend to affect a business combination by a merger structure to be determined involving the Company, one or more merger entities of the Company and WSL (the "Proposed Transaction"). "We believe the proposed merger could e

      3/15/23 8:00:00 AM ET
      $STAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $STAB
    SEC Filings

    See more
    • SEC Form DEFR14A filed by Statera Biopharma Inc.

      DEFR14A - Statera Biopharma, Inc. (0001318641) (Filer)

      2/28/23 9:06:58 PM ET
      $STAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Statera Biopharma Inc.

      DEF 14A - Statera Biopharma, Inc. (0001318641) (Filer)

      2/27/23 6:01:46 AM ET
      $STAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form PRE 14A filed by Statera Biopharma Inc.

      PRE 14A - Statera Biopharma, Inc. (0001318641) (Filer)

      2/15/23 9:08:28 AM ET
      $STAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $STAB
    Financials

    Live finance-specific insights

    See more
    • Tivic Health Acquires Exclusive Worldwide Rights to Phase III TLR5 Agonist from Statera Biopharma

      Broad licensing agreement accelerates Tivic's transformation into a diversified therapeutics company, adds late-stage immunotherapeutic to clinical pipeline. Potential for FDA approval within 24 months. Tivic Health Systems, Inc., (NASDAQ:TIVC) today announced it has acquired worldwide exclusive license rights from Statera Biopharma (OTC:STAB) to the late-stage Toll-like Receptor 5 (TLR5) agonist Entolimod™ for the treatment of acute radiation syndrome (ARS). In addition, the company has acquired an exclusive option to license five additional indications and clinical use cases for Entolimod and its derivative, Entalasta™. This broad licensing agreement establishes Tivic as a diversified t

      2/12/25 8:30:00 AM ET
      $STAB
      $TIVC
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
    • Statera Biopharma, Inc. Files Form 12b-25

      FORT COLLINS, Colo., March 31, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ:STAB) (the "Company" or "Statera Biopharma"), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced that the Company has filed a Form 12b-25 with the U.S. Securities and Exchange Commission to extend until April 15, 2022 the due date for filing the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2021. Statera Biopharma has been unable to complete its financial statements for the full year 2021 due to a delay experienced in completing its financial statements and other disclosures in t

      3/31/22 4:05:00 PM ET
      $STAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Statera Biopharma, Inc. to Report Fourth Quarter and Full Year 2021 Financial Results on March 31, 2022

      Live Conference Call and Webcast at 5:30 p.m. ET FORT COLLINS, Colo., March 28, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ:STAB) (the "Company" or "Statera Biopharma"), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, announced today that the Company will host a conference call and live audio webcast on Thursday, March 31, 2022, at 5:30 p.m. ET, to discuss its corporate and financial results for the fourth quarter and full year ended December 31, 2021. Conference Call & Webcast Details DateThursday, March 31, 2022Time5:30 p.m. ETLive Audio Webcasthttps://edge.media-server.com/mmc/p/yffrdzzpTeleph

      3/28/22 7:30:00 AM ET
      $STAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $STAB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Chandrasekhar Satishchandran

      3 - Statera Biopharma, Inc. (0001318641) (Issuer)

      3/21/22 7:27:04 PM ET
      $STAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Saluck Randy S. was granted 60,000 shares, increasing direct ownership by 42,857% to 60,140 units

      4 - Statera Biopharma, Inc. (0001318641) (Issuer)

      10/28/21 4:08:28 PM ET
      $STAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $STAB
    Leadership Updates

    Live Leadership Updates

    See more
    • Statera Biopharma Announces BF Borgers CPA PC as Independent Registered Public Accounting Firm

      FORT COLLINS, Colo., June 14, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ:STAB) (the "Company" or "Statera Biopharma"), a biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced the appointment of Certified Public Accountants, BF Borgers CPA PC as the Company's independent accountant to audit the balance sheet of the Company as of December 31, 2021, and the related statements of operations, stockholders' equity and income, and cash flows for the period ended December 31, 2021. About Statera BiopharmaStatera Biopharma, Inc. (formerly Cytocom, Inc.) is a clinical-stage biopharmaceutical company develo

      6/14/22 7:30:00 AM ET
      $STAB
      Biotechnology: Pharmaceutical Preparations
      Health Care